glp 1 gip gcg receptor agonist LY3437943, a novel triple glucagon, GIP, and GLP-1 for glycemic control and weight loss: From discovery to clinical proof of concept Glucagon Receptor Agonist - an

Description

Robert Kushner, who helped bring them to market, breaks down how they actually work, who benefits most, and why they're a long-term commitment rather than a quick fix

Lifestyle change is a critical step two

There is a reduced price if you pay in cash (Zebbound KwikPen) Members receive unlimited provider messaging and 1:1 health coaching support

In a 26-week RCT (PIONEER 5), involving 163 patients randomized to oral semaglutide (14 mg once daily) and 161 patients to the placebo, oral semaglutide was shown to provide a superior glycemic control (estimated treatment difference of 0.8%) and body weight loss (estimated treatment difference of 2.5 kg) than placebo and was found not to affect renal function